Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

Low-Pass Whole-Genome Sequencing of Circulating Cell-Free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

(2019) Xiaoji Chen et al.   CLINICAL CANCER RESEARCH

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

(2019) Corey J. Langer et al.   Journal of Thoracic Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

(2017) Jean-Charles Soria et al.   EUROPEAN JOURNAL OF CANCER

P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC

(2017) Matthew Krebs et al.   Journal of Thoracic Oncology

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

(2017) Leena Gandhi et al.   Journal of Thoracic Oncology

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib

(2017) Teresa Moran et al.   LUNG CANCER

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

(2017) Kirstine Jacobsen et al.   Nature Communications

1230PDPHASE 1B STUDY OF ORAL DUAL-PI3K/MTOR INHIBITOR GDC-0980 IN COMBINATION WITH CARBOPLATIN (CARBO)/PACLITAXEL (PAC) ± BEVACIZUMAB (BEV) AND CISPLATIN (CIS)/PEMETREXED (PEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS AND NSCLC

(2017) E. Calvo et al.   ANNALS OF ONCOLOGY

A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.

(2017) G. M. Blumenthal et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

(2017) R. B. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer

(2016) Noboru Yamamoto et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

(2015) P. N. Lara et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

(2015) Johan F. Vansteenkiste et al.   Journal of Thoracic Oncology

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

(2015) Matthias Scheffler et al.   Oncotarget

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

Classes of phosphoinositide 3-kinases at a glance

(2014) S. Jean et al.   JOURNAL OF CELL SCIENCE

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

(2014) Benjamin Levy et al.   Journal of Thoracic Oncology

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer

(2013) B. Besse et al.   ANNALS OF ONCOLOGY

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

(2013) D W Bowles et al.   BRITISH JOURNAL OF CANCER

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Molecular Dissection of AKT Activation in Lung Cancer Cell Lines

(2013) Yanan Guo et al.   MOLECULAR CANCER RESEARCH

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

(2012) J. M. Spoerke et al.   CLINICAL CANCER RESEARCH

The p110  and p110  isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

(2012) T. Utermark et al.   GENES & DEVELOPMENT

Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)

(2011) Meiju Ji et al.   BMC CANCER

The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion

(2011) Sze Ki Luk et al.   EUROPEAN JOURNAL OF CANCER

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

(2011) Johan Vansteenkiste et al.   Journal of Thoracic Oncology

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

(2011) Kenneth J O'Byrne et al.   LANCET ONCOLOGY

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study

(2011) K. Gately et al.   LUNG CANCER

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

(2010) Donatella Malanga et al.   CELL CYCLE

Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy

(2010) Yoh Dobashi   Frontiers in Bioscience-Landmark

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas

(2010) Yoh Dobashi et al.   HUMAN PATHOLOGY

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

Overexpression of the Mammalian Target of Rapamycin: A Novel Biomarker for Poor Survival in Resected Early Stage Non-small Cell Lung Cancer

(2010) Tony Dhillon et al.   Journal of Thoracic Oncology

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations

(2010) Miyako Hiramatsu et al.   LUNG CANCER

Activity of any class IA PI3K isoform can sustain cell proliferation and survival

(2010) L. C. Foukas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

(2008) Vincent Duronio   BIOCHEMICAL JOURNAL

Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas

(2008) Yoh Dobashi et al.   CANCER

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE